7 completed, 1 recruiting, 1 terminated, 1 unknown. 2 Not applicable, 2 Phase 2, 2 Phase 3, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow dolasetron: new trials by email Literature Review of dolasetron trials Research Report on dolasetron
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia Dolasetron mesylate injection - Chemotherapy Induced Nausea and Vomiting | Recruiting | Anhui Provincial Children's Hospital | 500 | 2024-11-21 | 2025-01-01 | |
| Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting HSK21542, Dolasetron - Nausea and Vomiting, Chemotherapy-Induced | Phase 2 | Unknown | First Affiliated Hospital of Wenzhou Medical University | 180 | 2024-09-16 | 2024-09-19 |
| Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Completed | Helsinn Healthcare SA | 414 | 2021-02-01 | 2025-12-02 |
| Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email - Postoperative Nausea and Vomiting | Not applicable | Completed | Vanderbilt University | 27034 | 2016-07-01 | 2019-03-07 |
| A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) Aprepitant, Aprepitant Placebo, Ondansetron - Nausea, Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 494 | 2012-12-12 | 2018-09-25 |
| The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects casopitant, dolasetron, granisetron - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 16 | 2007-07-23 | 2017-08-03 |
| Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy Aprepitant, Dexamethasone, Dolasetron Mesylate - Malignant Digestive System Neoplasm, Nausea and Vomiting | Not applicable | Terminated | University of Southern California | 19 | 2006-04-19 | 2017-03-28 |
| Efficacy of Dolasetron in Patients With Fibromyalgia Dolasetron, Placebo - Fibromyalgia | Phase 3 | Completed | University Hospital, Limoges | 60 | 2004-03-01 | 2025-07-16 |
| Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer dolasetron mesylate, granisetron hydrochloride, ondansetron - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 3 | Completed | Gary Morrow | 2001-07-01 | 2015-10-15 | |
| Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy dolasetron mesylate, granisetron hydrochloride, ondansetron - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 2 | Completed | Gary Morrow | 700 | 1999-10-01 | 2015-10-15 |
Vomiting (8) · Nausea (6) · Fibromyalgia (1) · Gastrointestinal Neoplasms (1) · Neoplasms (1) · Postoperative Nausea and Vomiting (1)
Gary Morrow (2) · Anhui Provincial Children's Hospital (1) · First Affiliated Hospital of Wenzhou Medical University (1) · GlaxoSmithKline (1) · Helsinn Healthcare SA (1) · Merck Sharp & Dohme LLC (1) · University Hospital, Limoges (1) · University of Southern California (1) · Vanderbilt University (1)
United States (5) · China (2) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Gary R. Morrow, PhD, MS (2) · Alex Molasiotis, prof. (1) · Betty Chan (1) · Jonathan P Wanderer, MD, MPhil (1)
PMID 12906958, PMID 16198982, PMID 19205754, PMID 21036635, PMID 27826874
P30CA014089 (1)